Yale University

University / College


Location: New Haven, CT, United States (USA) (US) US

ISNI: 0000000419368710

ROR: https://ror.org/03v76x132

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Vapor phase synthesis of topological semimetal MoP2nanowires and their resistivity (2022) Jin G, Han HJ, Hart JL, Sam QP, Kiani MT, Hynek DJ, Hasse V, et al. Journal article eQTL Set-Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma (2022) Wang X, Gharahkhani P, Levine DM, Fitzgerald RC, Gockel I, Corley DA, Risch HA, et al. Journal article HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Development of a 127Xe calibration source for nEXO (2022) Lenardo BG, Hardy CA, Tsang RH, Nzobadila Ondze JC, Piepke A, Triambak S, Jamil A, et al. Journal article Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US (2022) Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, et al. Journal article Engineering strong beamsplitter interaction between bosonic modes via quantum optimal control theory (2022) Basilewitsch D, Zhang Y, Girvin SM, Koch C Journal article Seizure semiology: ILAE glossary of terms and their significance (2022) Beniczky S, Tatum WO, Blumenfeld H, Stefan H, Mani J, Maillard L, Fahoum F, et al. Journal article KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer (2022) Mcarthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution [Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study (2022) Singh S, Pavel ME, Kunz PL, De Herder W, Herrmann K, D'Amelio AM, Santoro P, et al. Conference contribution X-Ray Coronal Properties of Swift/BAT-selected Seyfert 1 Active Galactic Nuclei (2022) Kamraj N, Brightman M, Harrison FA, Stern D, Garcia JA, Balokovic M, Ricci C, et al. Journal article